

Düsseldorf, Germany

Pitfalls & Artefacts 7 (Oncology) - Interactive **Wednesday, October 17, 08:00-09:30**

Session Title **PSMA Therapy**

Chairpersons

Boris Hadaschik (Essen)
Scott T. Tagawa (New York)

Programme

- | | |
|---------------|---|
| 08:00 - 08:15 | Boris Hadaschik (Essen): Setting the Stage - Where Does PSMA-Directed Radioligand Therapy Fit into the Urooncological Spectrum of Prostate Cancer Therapy |
| 08:15 - 08:35 | Scott T. Tagawa (New York): J591-PSMA Therapy and Important Pitfalls |
| 08:35 - 09:00 | Kambiz Rahbar (Münster): 177Lu-PSMA Therapy in Advanced Prostate Cancer and Corresponding Pitfalls |
| 09:00 - 09:15 | Matthias Eiber (Munich): 225Ac-PSMA Therapy in Advanced Prostate Cancer and Potential Pitfalls |
| 09:15 - 09:30 | General Discussion |

Educational Objectives

1. To Learn in Which Patients there is a medical need for PSMA-directed radioligand therapy
2. To Understand differences in PSMA-directed ligands (J591 vs. PSMA-617) and labelled radionuclides (177Lu vs. 225Ac) regarding biodistribution and side effects
3. To appreciate potential pitfalls and common/uncommon variations in PSMA-directed radioligand therapy

Summary

The success story of receptor-directed radioligand therapy is significantly impacting the field of nuclear medicine. FDA- and EMA-approval of Lutathera are now shifting the research focus to the numberwise even more relevant target prostate specific membrane antigen (PSMA). This session will start off with understanding when there is clinical need for PSMA-directed radioligand therapy. Then different ligands (J591 and PSMA 617) as well as different radionuclides (177Lu and 225Ac) will be individually introduced and their corresponding pitfalls presented. Finally, a general discussion involving all participants will take place to highlight the most relevant take home messages and make sure all non-addressed topics will be touched upon.

Keywords

PSMA therapy, 177Lu, 225Ac, CRPC, PSMA-617, J591